630 related articles for article (PubMed ID: 26474870)
1. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
2. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
[TBL] [Abstract][Full Text] [Related]
4. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
5. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
[TBL] [Abstract][Full Text] [Related]
6. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Cha SA; Park YM; Yun JS; Lim TS; Song KH; Yoo KD; Ahn YB; Ko SH
Lipids Health Dis; 2017 Apr; 16(1):58. PubMed ID: 28403877
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
[TBL] [Abstract][Full Text] [Related]
8. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
9. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
11. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).
de Boer SA; Heerspink HJL; Juárez Orozco LE; van Roon AM; Kamphuisen PW; Smit AJ; Slart RHJA; Lefrandt JD; Mulder DJ
Diabetes Obes Metab; 2017 Aug; 19(8):1147-1154. PubMed ID: 28244635
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
Persson F; Nyström T; Jørgensen ME; Carstensen B; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Eriksson JW; Norhammar A; Bodegard J; Birkeland KI
Diabetes Obes Metab; 2018 Feb; 20(2):344-351. PubMed ID: 28771923
[TBL] [Abstract][Full Text] [Related]
13. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
[TBL] [Abstract][Full Text] [Related]
15. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
Paty BW
Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
Sheu WH; Park SW; Gong Y; Pinnetti S; Bhattacharya S; Patel S; Seck T; Woerle HJ
Curr Med Res Opin; 2015 Mar; 31(3):503-12. PubMed ID: 25629790
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
Pérez-Belmonte LM; Osuna-Sánchez J; Millán-Gómez M; López-Carmona MD; Gómez-Doblas JJ; Cobos-Palacios L; Sanz-Cánovas J; Barbancho MA; Lara JP; Jiménez-Navarro M; Bernal-López MR; Gómez-Huelgas R
Ann Med; 2019; 51(3-4):252-261. PubMed ID: 31037970
[No Abstract] [Full Text] [Related]
18. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.
Deacon CF; Lebovitz HE
Diabetes Obes Metab; 2016 Apr; 18(4):333-47. PubMed ID: 26597596
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
